IDH1 and central nervous system cancer: Grade II/III IDH-mutant gliomas are classified in the World Health Organization 2016 standard by the presence of a 1p/19q co-deletion as oligodendroglioma (IDH-O) or as 1p/19q-intact astrocytoma (IDH-A) [7].